J&J Temporarily Halts Nevo Stent Trial, Citing Needed Catheter Improvements
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson has suspended enrollment in its NEVO II trial comparing its next-generation Nevo stent to Abbott's market-leading Xience V stent, citing needed improvements to the balloon catheter component of the system, the firm announced Oct. 19.
You may also be interested in...
And Then There Were Three: J&J/Cordis Exits Drug-Eluting Stent Market
The first company to enter the drug-eluting stent market will now be the first to depart.
And Then There Were Three: J&J/Cordis Exits Drug-Eluting Stent Market
The first company to enter the drug-eluting stent market will now be the first to depart.
J&J Nevo Stent Inhibits Tissue Proliferation Better Than Boston Sci’s Liberté
Johnson & Johnson/Cordis' Nevo next-generation sirolimus-eluting coronary stent inhibits tissue proliferation better than Boston Scientific's Taxus Liberté paclitaxel-eluting stent at six months, according to data from the NEVO RES-Elution I study unveiled May 19 at the EuroPCR meeting in Barcelona